Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Analysis (2024) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Kadmon Pharma, Sanofi, Anakuria, Regulus, Healx, XORTX, Poxel

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Autosomal Dominant Polycystic Kidney Disease therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Autosomal Dominant Polycystic Kidney Disease Therapeutics Market.

The report provides a detailed description of the Autosomal Dominant Polycystic Kidney Disease drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Autosomal Dominant Polycystic Kidney Disease Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Autosomal Dominant Polycystic Kidney Disease therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Autosomal Dominant Polycystic Kidney Disease treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Autosomal Dominant Polycystic Kidney Disease drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Autosomal Dominant Polycystic Kidney Disease treatment market.

Learn More about the Clinical and Commercial Development Activities in the Autosomal Dominant Polycystic Kidney Disease Therapeutics Domain @
https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Analysis
At present, there is no curative treatment for ADPKD and most available treatments focus on managing the associated complication, delaying kidney function decline, and slowing the cyst enlargement. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are preferred by most specialists who treat hypertension in ADPKD patients. In individuals with ADPKD, these drugs may be more effective in preserving kidney function and preventing left ventricular hypertrophy than other therapies for hypertension.

JYNARQUE/JINARC/SAMSCA (tolvaptan) developed by Otsuka Pharmaceutical is the only US FDA-approved therapy to treat adults with rapidly progressing ADPKD. There is a need for therapy that not only delays the disease progression but also completely cures it. With improved disease understanding, several companies like Xortx Therapeutics, Reata Pharmaceuticals/ Kyowa Kirin, Sanofi, Janssen Pharmaceuticals, Regulus Therapeutics, and others are conducting trials for molecules that target various pathways to control cyst formation or delay it. Currently, Reata Pharmaceuticals is leading the therapeutics marekt with its Autosomal dominant polycystic kidney disease drug candidates in the most advanced stage of clincial development.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Companies in the Therapeutics Market Include:
• Galapagos NV
• Reata Pharmaceuticals
• Kadmon Pharmaceuticals
• Sanofi
• Anakuria Therapeutics
• Regulus Therapeutics
• AceLink Therapeutics
• Healx
• XORTX Therapeutics
• Poxel
• Alebund Pharmaceuticals
• Chinook Therapeutics
And Many Others

Emerging and Marketed Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapies Covered in the Report Include:
• GLPG2737: Galapagos NV
• Bardoxolone methyl: Reata Pharmaceuticals
And Many More

Get an in-depth Assessment of the Emerging Therapies and Autosomal Dominant Polycystic Kidney Disease Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Autosomal Dominant Polycystic Kidney Disease Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Autosomal dominant polycystic kidney disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Request for Sample PDF to Understand More About the Autosomal Dominant Polycystic Kidney Disease Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Autosomal Dominant Polycystic Kidney Disease Current Treatment Patterns
4. Autosomal Dominant Polycystic Kidney Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Autosomal Dominant Polycystic Kidney Disease Late-Stage Products (Phase-III)
7. Autosomal Dominant Polycystic Kidney Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Autosomal Dominant Polycystic Kidney Disease Discontinued Products
13. Autosomal Dominant Polycystic Kidney Disease Product Profiles
14. Autosomal Dominant Polycystic Kidney Disease Companies
15. Autosomal Dominant Polycystic Kidney Disease Drugs
16. Dormant and Discontinued Products
17. Autosomal Dominant Polycystic Kidney Disease Unmet Needs
18. Autosomal Dominant Polycystic Kidney Disease Future Perspectives
19. Autosomal Dominant Polycystic Kidney Disease Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.